Home › Graft-Versus-Host Disease › Florida
Graft-Versus-Host Disease clinical trials in Florida
7 studies for Graft-Versus-Host Disease are looking for participants at sites in Florida.
Cities in Florida
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- University of Miami, Miami
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT05531786Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
- University of Miami Sylvester Comprehensive Cancer Center, Miami
Recruiting
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06910969Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
- Moffitt Cancer Center, Tampa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT06450925Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Moffitt Cancer Center, Tampa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- University of Miami, Miami
RecruitingPhase 2
Ages 2 and older · All sexes · Updated Jun 16, 2026 · NCT04710576A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- University of Miami, Miami
- Moffitt Cancer Center, Tampa
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT06615050A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- AdventHealth Orlando, Orlando
- Moffitt Cancer Center, Tampa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT06619561From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.